Hello Doctor,
Seeking your opinion regarding a 71-year-old patient diagnosed with NSCLC favor squamous cell carcinoma (P40 diffuse positive, TTF1 negative) involving the right upper lobe. PET-CT shows a spiculated RUL lesion approx. 3.0 × 4.7 × 4.0 cm with SUV max 16.58. Mildly FDG-avid hilar/paratracheal nodes (SUV ~4.2) with some calcification noted. EBUS/TBNA from stations 4R, 7 and 11L showed no evidence of malignancy. Current staging documented as cT2bN1M0 (Stage IIB). Proposed plan is neoadjuvant chemotherapy followed by reassessment for surgery.
Would appreciate guidance on:
1. Whether chemo + surgery appears the optimal curative-intent approach in this case.
2. Whether adding immunotherapy to neoadjuvant chemotherapy would significantly improve outcomes.
3. Whether current imaging/EBUS findings sufficiently support N1 staging or need further nodal evaluation.
Thank you.
My father is suffering from CLM (Chronic Myeloid Leukemia), Local Oncologist advised to take "BOSUTINIB 500 mg" but the Medicine doesn't suits on him, so many health issues arises after taking the Medicine. Earlier he was taking Tab "Imatinib 400" since 2018. Now patellate count has increased,& Hb is very low, Please Guide what to do now
My mother right breast 3 cm lump and biopsy report invasive carnicoma can you tell me please what Is the treatment
Hi, I'm 24 years old female. I feel a hard lump on one of my underarm. It is hard like a bone. I feel uncomfortable if I bring my arm closer to my chest. I fear of this can be a symptom of breast cancer.
Seeking expert opinion for a 62F with signet ring cell carcinoma of sigmoid colon diagnosed July 2025. She underwent surgery (LAR + hysterectomy + BSO) followed by chemotherapy (Dacotin + Capecitabine). Latest PET-CT Feb 2026 shows no liver, lung, brain metastasis and no residual primary lesion. However, there are FDG-avid peritoneal nodules (SUV ~7) with mild ascites, suggestive of post-op changes vs residual disease. Kindly advise on further management, chemotherapy strategy, CRS alone or CRS with HIPEC suitability or second line chemo.
